FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116150249> ?p ?o ?g. }

• W2116150249 endingPage "267" @default.
• W2116150249 startingPage "267" @default.
• W2116150249 abstract "In recent years, new strategies for treating melanoma have been introduced, improving the outlook for this challenging disease. One of the most important advances has been the development of immunotherapy. The better understanding of the role of the immunological system in tumor control has paved the way for strategies to enhance the immune response against cancer cells. Monoclonal antibodies (mAbs) against the immune checkpoints cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have demonstrated high activity in melanoma and other tumors. Ipilimumab, an anti CTLA-4 antibody, was the first drug of this class that was approved. Although the response rate with ipilimumab is low (less than 20% of patients have objective responses), 20% of patients have long survival, with similar results in the first and second line settings. Nivolumab and pembrolizumab, both anti PD-1 inhibitors, have been approved for the treatment of melanoma, with response rates of 40% and a demonstrated survival advantage in phase III trials. This has marked a new era in the treatment of metastatic melanoma and much research is now ongoing with other drugs targeting checkpoint inhibitors. In addition, the agonist of activating molecules on T cells and their combinations are being investigated. Herein we review the clinical development of checkpoint inhibitors and their approval for treatment of metastatic melanoma." @default.
• W2116150249 created "2016-06-24" @default.
• W2116150249 creator A5012702634 @default.
• W2116150249 creator A5026259717 @default.
• W2116150249 creator A5028314830 @default.
• W2116150249 creator A5068271097 @default.
• W2116150249 creator A5068684456 @default.
• W2116150249 creator A5072143967 @default.
• W2116150249 creator A5076460757 @default.
• W2116150249 date "2015-10-01" @default.
• W2116150249 modified "2023-10-18" @default.
• W2116150249 title "Immune checkpoint inhibitors: therapeutic advances in melanoma." @default.
• W2116150249 cites W1423342398 @default.
• W2116150249 cites W1572739876 @default.
• W2116150249 cites W1809627231 @default.
• W2116150249 cites W1884940699 @default.
• W2116150249 cites W1920235745 @default.
• W2116150249 cites W1936956202 @default.
• W2116150249 cites W1967084952 @default.
• W2116150249 cites W1975926179 @default.
• W2116150249 cites W1977417864 @default.
• W2116150249 cites W1982391739 @default.
• W2116150249 cites W1982734162 @default.
• W2116150249 cites W1983580311 @default.
• W2116150249 cites W1984727851 @default.
• W2116150249 cites W1988555834 @default.
• W2116150249 cites W1990675339 @default.
• W2116150249 cites W2004312434 @default.
• W2116150249 cites W2010121426 @default.
• W2116150249 cites W2016983859 @default.
• W2116150249 cites W2019035934 @default.
• W2116150249 cites W2020090293 @default.
• W2116150249 cites W2028376975 @default.
• W2116150249 cites W2038914273 @default.
• W2116150249 cites W2039123767 @default.
• W2116150249 cites W2040851929 @default.
• W2116150249 cites W2050407789 @default.
• W2116150249 cites W2052855154 @default.
• W2116150249 cites W2070825440 @default.
• W2116150249 cites W2071882245 @default.
• W2116150249 cites W2075873658 @default.
• W2116150249 cites W2078607441 @default.
• W2116150249 cites W2082158071 @default.
• W2116150249 cites W2089103836 @default.
• W2116150249 cites W2095826876 @default.
• W2116150249 cites W2097995306 @default.
• W2116150249 cites W2100158834 @default.
• W2116150249 cites W2101653483 @default.
• W2116150249 cites W2104885590 @default.
• W2116150249 cites W2107075226 @default.
• W2116150249 cites W2107484016 @default.
• W2116150249 cites W2112121482 @default.
• W2116150249 cites W2112123471 @default.
• W2116150249 cites W2112853593 @default.
• W2116150249 cites W2116317906 @default.
• W2116150249 cites W2117443086 @default.
• W2116150249 cites W2118546263 @default.
• W2116150249 cites W2118982164 @default.
• W2116150249 cites W2119198740 @default.
• W2116150249 cites W2121080857 @default.
• W2116150249 cites W2123363005 @default.
• W2116150249 cites W2124427232 @default.
• W2116150249 cites W2126259300 @default.
• W2116150249 cites W2127863254 @default.
• W2116150249 cites W2128035403 @default.
• W2116150249 cites W2128542677 @default.
• W2116150249 cites W2128758225 @default.
• W2116150249 cites W2130819559 @default.
• W2116150249 cites W2133075384 @default.
• W2116150249 cites W2134435470 @default.
• W2116150249 cites W2134644618 @default.
• W2116150249 cites W2135707184 @default.
• W2116150249 cites W2136746908 @default.
• W2116150249 cites W2139591061 @default.
• W2116150249 cites W2141579931 @default.
• W2116150249 cites W2142604595 @default.
• W2116150249 cites W2143163879 @default.
• W2116150249 cites W2152897456 @default.
• W2116150249 cites W2154506633 @default.
• W2116150249 cites W2160834915 @default.
• W2116150249 cites W2161550811 @default.
• W2116150249 cites W2166662937 @default.
• W2116150249 cites W2172743297 @default.
• W2116150249 cites W2328314409 @default.
• W2116150249 cites W2344221521 @default.
• W2116150249 cites W2396754672 @default.
• W2116150249 cites W2560367415 @default.
• W2116150249 cites W2572174216 @default.
• W2116150249 cites W4241093956 @default.
• W2116150249 doi "https://doi.org/10.3978/j.issn.2305-5839.2015.10.27" @default.
• W2116150249 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4630549" @default.
• W2116150249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26605313" @default.
• W2116150249 hasPublicationYear "2015" @default.
• W2116150249 type Work @default.
• W2116150249 sameAs 2116150249 @default.
• W2116150249 citedByCount "41" @default.
• W2116150249 countsByYear W21161502492016 @default.
• W2116150249 countsByYear W21161502492017 @default.

• next